geographic atrophy
Jump to navigation
Jump to search
Etiology
- macular degeneration
- advanced dry form of age-related macular degeneration
Epidemiology
- affects > 1 million people in the U.S. & 5 million people worldwide
Complications
- major cause of adult blindness
Management
- pegcetacoplan (Syfovre) injection administered every 25-60 days (FDA-approved)
- maximum benefit between 18-24 months after initiating treatment.
- avacincaptad pegol (Izeray)
More general terms
References
- ↑ Marcus A FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. Medscape. February 17, 2023 https://www.medscape.com/viewarticle/988460